Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
blue cross blue shield glp-1 coverage 2026 Independence to stop covering agonists Wegovy, Ozempic as weight loss drugs in 2025 Coverage of Obesity Therapies Diet Type_Diabetic Friendly Months:3 Month
Coverage of Obesity Therapies in State-Regulated Markets
Tirzepatide is unique because it targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, making it a dual agonist
Diet Type_Diabetic Friendly
Months:3 Month
11 It was later determined that higher concentrations were necessary to produce the same effect in vivo
US$ 22.68
US$ 26.89
US$ 22.82
